Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis

NCT06590428 is registered in ClinicalTrials.gov with Albert Einstein College of Medicine as lead sponsor.

NCT NCT06590428
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06590428 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Lead sponsor
Albert Einstein College of Medicine
Phase
Not applicable
Overall status
Recruiting
Start date
April 7, 2026
Completion date
December 31, 2029
Enrollment
280 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug-resistant tuberculosis, rifampin-resistant tuberculosis